pharma · Opioid Use Disorder · Opioid Dependence
Indivior Pty
Indivior Pty Ltd
Indivior is a pharma organization headquartered in Richmond, USA. Primary therapeutic focus areas include Opioid Use Disorder, Opioid Dependence, Schizophrenia, Opioid Dependency, Opiate Dependence. NovaPharmaNews links
., Richmond, VA, US HQ
967 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- ., Richmond, VA, US
- Employees
- 967
- Programs
- 39
- Drugs
- 19
- Patents
- 34
Transmucosal Buprenorphine
Approved · small molecule · Moderate to Severe Opioid-use Disorder
Transmucosal Buprenorphine for Moderate to Severe Opioid-use Disorder is a Approved program (small_molecule) at Indivior Pty Ltd with 1 ClinicalTrials.gov record(s).
Internal code INDV-6000-401
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Indivior Pty Ltd
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Moderate to Severe Opioid-use Disorder
- Status
- completed
- Trials
- 1